The Billionaires Fueling the Quest for Longer Life
Thermal Clients Featured in WSJ Longevity Investment Deep Dive
Wall Street Journal spotlights the billionaire-backed longevity sector in a comprehensive analysis—featuring two Thermal clients at the center of the boom.
Retro Biosciences earned prominent placement as Sam Altman’s $180 million bet on cellular rejuvenation. The piece details Retro’s approach to developing drugs that reprogram aging cells, with CEO Joe Betts-LaCroix (formerly of Halcyon Molecular) leading the charge.
BioAge Labs was highlighted multiple times as a key player among the nearly 60 biotechs that have collectively raised $5 billion in the space. The article noted BioAge’s 2024 public debut and its current clinical programs targeting age-related diseases.
The WSJ identified three core investment themes driving the $5+ billion influx: cellular rejuvenation/healthspan extension (Retro’s domain), treatments for age-related diseases (BioAge’s focus), and longevity supplements/services.
Key investors profiled include Thiel, Altman, Milner, and Andreessen—with the piece mapping their interconnected portfolio companies and the network effects accelerating the sector’s growth.
